Heparin Or Derivative Patents (Class 514/56)
  • Patent number: 10493012
    Abstract: Affinity purification of fibroblast growth factor 2-binding heparan sulphate from porcine mucosa (HS8) is disclosed. Also disclosed is a process for the care of keratinous material(s), comprising the application or administration of HS8, or a composition comprising thereof, to keratinous material(s). The composition may be used to improve the condition of skin, such as smoothing the skin, restoring skin elasticity and firmness, or decreasing or preventing wrinkles, and may be formulated for topical or transdermal administration.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: December 3, 2019
    Assignees: Agency for Science, Technology and Research, L'Oreal
    Inventors: Simon Cool, Victor Nurcombe, Charbel Bouez, Diah Saraswati Bramono
  • Patent number: 10206392
    Abstract: The present invention relates to a disinfecting composition which requires a shorter contact time to be effective than similar compositions. Also, provided is a method of disinfecting a surface with the disinfecting composition where a shorter contact time is needed to disinfect the surface.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: February 19, 2019
    Assignee: Lonza, Inc.
    Inventors: Andrew Kloeppel, James Bargmann
  • Patent number: 10188110
    Abstract: A catheter lock solution includes a hydrochloric acid solution having a concentration of 0.3 Molar to 1.0 Molar. This hydrochloric acid solution may be used to lock a catheter and/or salvage an infected catheter.
    Type: Grant
    Filed: April 18, 2016
    Date of Patent: January 29, 2019
    Assignee: Teleflex Medical Incorporated
    Inventors: Nisha Gupta, Elaine Steinke, Joel Rosenblatt
  • Patent number: 10172938
    Abstract: A responsive hydrogel-based material may be used as a carrier system for the in situ delivery of various cargo substances, including bioactive moieties. The hydrogel structure, which includes photodegradable and thioether moieties in its three dimensional network, enables finely tuned local release of cargo substances as a function of the in vivo tissue environment (e.g., enzyme concentration or reducing environment) and externally applied stimuli (e.g., light) by selective spatiotemporal hydrogel degradation.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: January 8, 2019
    Assignees: University of Delaware, The Regents of the University of California
    Inventors: Kristi L. Kiick, April M. Kloxin, Prathamesh M. Kharkar, Raja Sivamani, Emanual Maverakis
  • Patent number: 10021876
    Abstract: A composition that can solvate biofilms and disrupt bacterial cell walls acts to both kill the bacteria by cell lysis and remove the biofilm. This solvent-containing composition is effective against a broad spectrum of microbes and can be used on a variety of surfaces, both living and inanimate. The polarity of the solvent component of the composition is lower than that of pure water so that the composition exhibits increased efficacy in solvating the macromolecular matrix of a biofilm and in penetrating bacterial cell walls.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: July 17, 2018
    Assignee: Next Science IP Holdings Pty Ltd
    Inventor: Matthew Franco Myntti
  • Patent number: 10023659
    Abstract: The present invention relates to a process for the production of heparin derivatives having an average molecular weight of from about 4.6 to about 6.9 kDa and an anti-factor Xa activity of less than about 10 IU/mg, comprising the steps of oxidation of unfractionated heparin, depolymerisation and reduction of resulting terminal groups.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: July 17, 2018
    Assignee: Dilafor AB
    Inventors: Per-Olov Eriksson, Erik Yngve Holmer
  • Patent number: 9999649
    Abstract: Provided are a cosmetic composition and pharmaceutical composition for wound healing capable of efficiently performing collagen synthesis in skin, wherein the compositions contain, as an active ingredient, YIGSR peptide having the amino acid sequence of SEQ ID NO: 1 or a peptide derivative having a palmitoyl group added to an N-terminal of the peptide.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: June 19, 2018
    Assignee: NOVACELL TECHNOLOGY INC.
    Inventors: Tae Hoon Lee, Jae Yoon Kim, Jong Hyuk Yoon, Beom Joon Kim
  • Patent number: 9861655
    Abstract: The present invention relates to advanced topical formulations of pharmaceutically acceptable salts of Heparin providing enhanced transdermal penetration. The present invention provides clear, non-sticky liquid formulations in which the drug is ready-for-absorption and which are suitable for administration in the form of a solution or a spray. The topical formulations of the present invention do not form flaky or gel-like film on skin surface upon topical application.
    Type: Grant
    Filed: February 10, 2015
    Date of Patent: January 9, 2018
    Assignee: Troikaa Pharmaceuticals Limited
    Inventors: Ketan R. Patel, Milan R. Patel, Asheel K. Patel, Prakash J. Shah
  • Patent number: 9833618
    Abstract: Methods for treating a disease condition in a subject are provided. The subject methods include selectively modulating at least one biological activity of advential tissue in a manner effective to treat the disease condition. Also provided are compositions, kits and systems for use in practicing the subject methods.
    Type: Grant
    Filed: January 30, 2006
    Date of Patent: December 5, 2017
    Assignee: Palo Alto Investors
    Inventor: Anthony Joonkyoo Yun
  • Patent number: 9649499
    Abstract: A method for passivating a biomaterial surface includes modifying proteinaceous material disposed at the biomaterial surface. The passivation may be effectuated by exposing the biomaterial surface to therapeutic electrical energy in the presence of blood or plasma.
    Type: Grant
    Filed: March 28, 2008
    Date of Patent: May 16, 2017
    Assignee: Medtronic ATS Medical, Inc.
    Inventor: Brian Pederson
  • Patent number: 9629914
    Abstract: Biomaterial compositions that include an isolated heparosan polymer are disclosed, as well as kits containing such biomaterial compositions and methods of producing and using such biomaterial compositions.
    Type: Grant
    Filed: October 22, 2013
    Date of Patent: April 25, 2017
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Paul L. DeAngelis
  • Patent number: 9629856
    Abstract: The present invention provides compositions containing one or more antimicrobial peptide sequestering compounds and methods for topical application of such compositions to the skin to treat skin diseases and disorders such as rosacea in humans.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: April 25, 2017
    Assignee: Anteis SA
    Inventor: Frank Dreher
  • Patent number: 9480702
    Abstract: The present invention relates to chemically modified heparin for use in the treatment of sickle cell disease, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: November 1, 2016
    Assignee: DILAFORETTE AB
    Inventors: Hans-Peter Ekre, Anna Leitgeb, Mats Wahlgren, Dagmar Pikas
  • Patent number: 9480701
    Abstract: The present invention relates to a chemically modified heparin, with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw) between about 6.5 and 9.5 kDa. Also disclosed is a method of preparing the heparin and its medical use, including treatment of malaria.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: November 1, 2016
    Assignee: DILAFORETTE AB
    Inventors: Hans-Peter Ekre, Ulf Lindahl, Erik Holmer, Per-Olov Eriksson, Anna Leitgeb, Mats Wahlgren, Stefania Tiddia, Lino Liverani
  • Patent number: 9475888
    Abstract: The present invention relates to a chemically modified glycosaminoglycan with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw, weight average) from about 4.6 to 6.9 kDa. Also disclosed is a method of preparing the modified glycosaminoglycan and its medical uses.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: October 25, 2016
    Assignee: Dilafor AB
    Inventors: Hans-Peter Ekre, Ulf Lindahl, Erik Holmer, Per-Olov Eriksson
  • Patent number: 9259389
    Abstract: The present invention concerns a pharmaceutical formulation intended for oral administration containing a synthetic oligosaccharides containing one to 18 monosaccharide units and having a therapeutical activity or a pharmaceutically acceptable additions salt or solvate thereof wherein the formulation contains: a) the synthetic oligosaccharide (A) in an amount of up to 5% by weight of the total weight of the formulation, advantageously up to 1% by weight of the total weight of the formulation, b), a lipophilic phase (B) consisting of triglyceride of fatty acids in an amount of 50 to 80% by weight of the total weight of the formulation, advantageously of 50 to 70% by weight of the total weight of the formulation, c) at least one lipophilic surfactant (C) with HLB below 7 consisting of partial esters of polyol and fatty acids in an amount of 10 to 30% by weight of the total weight of the formulation, advantageously of 15 to 30% by weight of the total weight of the formulation, d) at least one hydrophilic surfact
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: February 16, 2016
    Assignees: ENDOTIS PHARMA, CATALENT FRANCE BEINHEIM SA
    Inventors: Julien Meissonnier, Nathalie Sicre, Guillaume Sabate, Guy Dubreucq, Vanessa Nancy-Portebois, Maurice Petitou
  • Patent number: 9212233
    Abstract: Polysaccharide preparations lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.
    Type: Grant
    Filed: September 27, 2013
    Date of Patent: December 15, 2015
    Assignee: MOMENTA PHARMACEUTICALS, INC.
    Inventors: Mallikarjun Sundaram, Takashi Kei Kishimoto, Sucharita Roy
  • Patent number: 9205106
    Abstract: The use of Herapan Sulphate 2 (HS-2) in therapeutic bone growth and regeneration is described. Herapan Sulphate 2 was identified as a variant of Heparan Sulphate purified from embryonic day (E10) of murine neuroepithelia.
    Type: Grant
    Filed: September 7, 2009
    Date of Patent: December 8, 2015
    Assignee: Agency for Science, Technology and Research
    Inventors: Simon McKenzie Cool, Victor Nurcombe
  • Patent number: 9155756
    Abstract: This invention is in the field of medical treatment, in particular the invention provides a method for the prevention and treatment for sepsis or septic shock. The invention provides a novel use of a known medicament, i.e., pentasaccharide-depleted heparin, for use in the treatment or prevention of sepsis, systemic inflammatory response syndrome, severe sepsis or septic shock.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: October 13, 2015
    Assignees: Universiteit Maastricht, Academisch Ziekenhuis Maastricht
    Inventors: Gerardus Anna Franciscus Nicolaes, Christiaan Peter Maria Reutelingsperger, Hendrik Coenraad Hemker
  • Patent number: 9062194
    Abstract: A method for preparing a solid composite material comprising a structural polymer matrix and a thermo-responsive hydrogel involves forming a substantially homogeneous blend of a cross-linkable compound and monomer, oligomer or polymer particles in a blended aqueous liquid, inducing the cross-linkable compound to cross-link to form the thermo-responsive hydrogel and forming the structural polymer matrix from the structural polymer by a further induction means, wherein the resulting solid composite material provides a textile or membrane which presents a thermally insulating layer, through which air and/or liquid water cannot easily pass at low temperatures, but which also provides a more open structure at higher temperatures so that air and moisture vapor can pass through the textile or membrane.
    Type: Grant
    Filed: November 5, 2012
    Date of Patent: June 23, 2015
    Assignees: WETENSCHAPPELIJK EN TECHNISCH CENTRUM VAN DE BELGISCHE TEXTIELNIJVERHEID, UNIVERSITEIT GENT
    Inventors: Geert Hebbrecht, Peter Dubruel, Myriam Vanneste, Jan Laperre, Etienne Schacht, Jorg Schelfhout
  • Publication number: 20150147379
    Abstract: The embodiments relate generally to medical devices and to methods of their manufacture. One aspect provides devices including chitosan fibers that are a free of chemical cross linking. Another aspect provides a method of manufacturing such devices.
    Type: Application
    Filed: November 18, 2014
    Publication date: May 28, 2015
    Applicant: COOK MEDICAL TECHNOLOGIES LLC
    Inventor: Mohammad Z. Albanna
  • Publication number: 20150139938
    Abstract: The present invention provides methods of promoting arteriogenesis in a subject. Embodiments include methods comprising: administering an effective dose of tocotrienol to the subject; causing an increase in Tissue Inhibitor of Metalloproteinase Metallopeptidase Inhibitor 1 (TIMP1) in vessels of cerebrovascular collateral circulation in the subject; attenuating the activity of Matrix Metalloproteinase-2 (MMP2); thereby promoting arteriogenesis.
    Type: Application
    Filed: June 7, 2013
    Publication date: May 21, 2015
    Applicant: Ohio State Innovation Foundation
    Inventors: Chandan Sen, Cameron Rink, Sashwati Roy, Greg Christoforidis
  • Publication number: 20150140106
    Abstract: An ophthalmic formulation that includes nanoparticles. Each nanoparticle includes a shell which encapsulates sulfated non-anticoagulant heparin (SNACH), with or without hydrophobic anti-angiogenesis Tyrosine Kinase inhibitors. The SNACH is ionically or covalently bonded to the shell. The shell includes a polymer selected from the group consisting of poly (lactic-co-glycolic acid) (PLGA), chitosan, chitosan-alginate, and NIPAAM-APMAH-AA, wherein NIPAAM is N-isopropyl acrylamide, APMAH is N-3-aminopropylmethacrylamide hydrochloride, and AA is acrylic acid. A method for treating an eye disease of a subject includes: administering to an eye of the subject a therapeutically effective amount of the ophthalmic formulation for treating the eye disease. The eye disease involves an ocular angiogenesis-mediated disorder.
    Type: Application
    Filed: October 29, 2014
    Publication date: May 21, 2015
    Inventor: Shaker A. Mousa
  • Publication number: 20150126473
    Abstract: The present disclosure provides an isolated particle comprising very high density, ultra small, lipid depleted apo B containing particles, and may also contain cytokeratin 8. The isolated particle is useful in diagnostic assays, which are also provided.
    Type: Application
    Filed: June 14, 2012
    Publication date: May 7, 2015
    Applicant: Children's Hospital & Research Center at Oakland
    Inventors: Ronald M. Krauss, Mohmed Elfatih Ashmaig
  • Patent number: 9018372
    Abstract: The invention relates to a bonding product comprising at least the polysaccharides T1 and T2, characterized in that a) the monosaccharides from which the polysaccharides T1 and T2 are constructed are partially or completely bonded to each other alpha-1,4-glycosidically and b) at least one of the polysaccharides T1 and/or T2 comprises at least one amino group and c) T1 and T2 are chemically bonded to each other covalently by at least one linker Z and d) T1 and/or T2 carries m groups -(L-A), wherein A is an active pharmaceutical ingredient and/or a fluorescence label, L is a second linker, by which T1 and/or T2 is covalently bonded to A, and m is an integer, which is 0 or at least 1.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: April 28, 2015
    Assignee: B. Braun Melsungen AG
    Inventors: Bernd Horst Meier, Iris Jankowiak-Meier, Nele Meier, Clara Meier
  • Publication number: 20150112424
    Abstract: A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said first and second pharmaceutical agents are selected from two different classes of pharmaceutical agents.
    Type: Application
    Filed: August 29, 2014
    Publication date: April 23, 2015
    Inventors: James DeYoung, Doug Taylor, Jim McClain, Clint Smoke, Mike Cole
  • Publication number: 20150111849
    Abstract: The method is described as the removal of mediators that contribute to the pathogenesis of cancer from blood by contacting the blood with a solid, essentially non-micro-porous substrate which has been surface treated with heparin, heparan sulfate and, optionally, other molecules or chemical groups (the adsorbent media or media) having a binding affinity to the mediator, and wherein the size of the interstitial channels within said substrate are balanced with the amount of interstitial substrate surface area such that high flow rates of blood past said substrate creates a flow transport that is characterized by convection transport more than Brownian diffusion transport.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 23, 2015
    Inventors: KEITH MCCREA, ROBERT WARD, OLLE LARM
  • Patent number: 9012396
    Abstract: In one embodiment, the invention provides a method of suppressing, inhibiting, preventing, or treating conjunctivitis in a subject, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound via an ester or amide bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof to a subject with conjunctivitis.
    Type: Grant
    Filed: January 9, 2013
    Date of Patent: April 21, 2015
    Assignee: Yissum Research Development Company of The Hebrew University of Jerusalem
    Inventor: Saul Yedgar
  • Publication number: 20150105345
    Abstract: Described herein is the finding that hyaluronan antagonists that inhibit hyaluronan signaling are capable of inhibiting airway inflammation and airway hyperresponsiveness (AHR). The present disclosure provides a method of preventing or reducing AHR in a subject suffering from or at risk for AHR by administering a hyaluronan antagonist. Also provided is a method of treating an airway disease or disorder in a subject by administering a hyaluronan antagonist. Hyaluronan antagonists include, for example, heparosan and hyaluronan oligosaccharides (oHAs). In some embodiments, the hyaluronan antagonist is administered locally to the airway, such as with an inhaler or nebulizer.
    Type: Application
    Filed: March 8, 2013
    Publication date: April 16, 2015
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, Duke University, MUSC Foundation for Research Development, The Universtiy of North Carolina at Chapel Hill
    Inventors: Stavros Garantziotis, John W. Hollingsworth, Bryan P. Toole, Jian Liu
  • Publication number: 20150099718
    Abstract: The invention provides the use in combination of a heparin containing composition that has anticoagulant activity when used alone, such as an unfractionated heparin or low molecular weight heparin, in combination with an inhibitor of the anticoagulation activity/effect or effect of heparin, for the inhibition of metastasis.
    Type: Application
    Filed: December 9, 2014
    Publication date: April 9, 2015
    Inventor: Eugene J. Oliva
  • Publication number: 20150099703
    Abstract: The present invention refers to the use of certain sulfated glycosaminoglycans for treatment or prevention of postpartum haemorrhage. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are administered in combination with at least one uterotonic agent capable of promoting myometrial contractions of the uterus and thereby compress the vessels and cease the bleeding.
    Type: Application
    Filed: May 7, 2013
    Publication date: April 9, 2015
    Inventors: Gunvor Ekman-Ordeberg, Anders Malmström
  • Patent number: 8999340
    Abstract: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and/or an inhibitor of interferon alpha, and the use of the compositions in methods for treating or preventing Degos' disease in a subject. In some embodiments, the inhibitor is an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or to a biologically-active fragment of C5 such as C5a or C5b. In some embodiments, the inhibitor is an antibody, or an antigen-binding fragment thereof, that binds to interferon alpha or to an interferon alpha receptor.
    Type: Grant
    Filed: March 1, 2011
    Date of Patent: April 7, 2015
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventor: Cynthia Magro
  • Patent number: 8992963
    Abstract: There is described inter alia a medical device having a surface which comprises a coating layer, said coating layer being a biocompatible composition comprising an entity capable of interacting with mammalian blood to prevent coagulation or thrombus formation, which entity is covalently attached to said surface through a link comprising a 1,2,3-triazole.
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: March 31, 2015
    Assignee: Carmeda AB
    Inventors: Stefan Oscarson, Martina Lahmann, Karin Leontein, Robert Vestberg
  • Publication number: 20150086565
    Abstract: Proteomic methods for identifying cancer related proteins and related products and kits are provided. The cancer specific proteins are extracellular matrix proteins that are associated with various aspects of cancer. Panels or signature sets of proteins useful in the detection, diagnosis and treatment of cancers as well as monitoring therapeutic progress in a cancer patient are provided herein along with methods for their detection and for their use in targeting imaging and/or therapeutic agents to the tumors via binding to the specified proteins. The proteins were identified using proteomics analyses of tissue samples taken from cancer patients. In certain aspects the proteins are particularly useful in colon cancer patients.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 26, 2015
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporaiton d/b/a Massachusetts General Hospital, The Broad Institute, Inc.
    Inventors: Richard O. Hynes, Alexandra Naba, Karl Clauser, Steven A. Carr, Kenneth Tanabe
  • Patent number: 8987231
    Abstract: The present invention describes sulodexide or at least one of its components for use in the reduction of circulating matrix metalloproteinase (MMPs), in particular MMP-9. Sulodexide and its composition are useful for the treatment of pathologies wherein the MMPs are involved, such as cardiovascular disease, cardiovascular disease caused by diabetes, varicose veins, chronic venous insufficiency (CVI), gastrointestinal ulcers, pulmonary disease, and neoplastic pathologies.
    Type: Grant
    Filed: April 20, 2011
    Date of Patent: March 24, 2015
    Assignee: Alfa Wassermann S.p.A.
    Inventors: Giuseppe Claudio Viscomi, Ferdinando Mannello, Cristiana Bruno
  • Publication number: 20150065456
    Abstract: The invention provides methods of treating or preventing in a subject a cancer, tumor, or neoplasm, including malignancies or metastases thereof, using a direct Factor Xa inhibitor. The methods particularly involve the treatment of human patients afflicted with a malignant cancer, tumor, or neoplasm with an effective amount of the Factor Xa inhibitor. In an embodiment, the Factor Xa inhibitor is the small molecule edoxaban p-toluenesulfonate monohydrate, also termed “DU-176b”. The invention provides methods of administering a Factor Xa inhibitor to effectively reduce or suppress, or otherwise abrogate, the growth of cancers, tumors, or neoplasms in a subject who has, or is at risk for, cancer and, optionally, who also has, or is at risk for, thrombotic disease or embolism. The methods of the invention can also reduce the incidence of migration or invasion of metastatic or malignant cancers in a human subject by administration of a Factor Xa inhibitor.
    Type: Application
    Filed: August 28, 2014
    Publication date: March 5, 2015
    Inventor: Michele Mercuri
  • Publication number: 20150065455
    Abstract: The invention relates to assessing the Fc?RIIIa-158 polymorphism in a subject in order to determine susceptibility of the subject to drug induced thrombocytopenia, as well as therapies and therapeutic compositions based on the use of this biomarker.
    Type: Application
    Filed: March 6, 2014
    Publication date: March 5, 2015
    Inventors: Herve Watier, Yves Gruel, Claire Pouplard
  • Patent number: 8969319
    Abstract: An agent for applying to mucosa capable of persistently exerting a therapeutic effect on disorders such as inflammation and lesions in the mucosa even by a lower frequency of administration because the agent can stay at a diseased site for a long period of time by exhibiting a high staying property in a mucosal epithelial layer is provided, said agent for application to mucosa containing glycosaminoglycan (GAG) into which a hydrophobic group is introduced via a binding chain, as an active ingredient.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: March 3, 2015
    Assignee: Seikagaku Corporation
    Inventors: Kenji Miyamoto, Katsuya Takahishi, Yuuji Shimojima
  • Publication number: 20150057237
    Abstract: The present invention relates to a modular supramolecular bioresorbable or biomedical material comprising (i) a polymer comprising at least two 4H-units and (ii) a biologically active compound. Optionally, the supramolecular bioresorbable or biomedical material comprises a bioresorbable or biomedical polymer as third component to tune its properties (mechanical and bioresorption properties). The supramolecular bioresorbable or biomedical material is especially suitable for biomedical applications such as controlled release of drugs, materials for tissue-engineering, materials for the manufacture of a prosthesis or an implant, medical imaging technologies.
    Type: Application
    Filed: October 29, 2014
    Publication date: February 26, 2015
    Applicant: SupraPolix B.V.
    Inventors: Patricia Yvonne Wilhelmina DANKERS, Gaby Maria Leonarda HOORNE-VAN GEMERT, Henricus Marie JANSSEN, Egbert Willem MEIJER, Anton Willem BOSMAN
  • Publication number: 20150050325
    Abstract: The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to a drug-eluting stent comprising said compounds and methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery.
    Type: Application
    Filed: January 16, 2013
    Publication date: February 19, 2015
    Applicant: The Rockefeller University
    Inventors: Barry S. Coller, Craig Thomas, Marta Filizola, Joshua McCoy, Wenwei Huang, Min Shen, Jian-Kang Jiang
  • Publication number: 20150045322
    Abstract: The present invention refers to the use of certain sulfated glycosaminoglycans for inducing labor. The sulfated glycosaminoglycans have a reduced anticoagulant activity and are used in a combination therapy together with treatment capable of promoting cervical ripening or capable of promoting myometrial contractions of the uterus.
    Type: Application
    Filed: March 25, 2013
    Publication date: February 12, 2015
    Inventors: Gunvor EKMAN-ORDEBERG, Anders MALMSTRÖM
  • Publication number: 20150037341
    Abstract: The present invention relates to a method of treating or preventing transthyretin amyloidosis, pharmaceutical composition for use in said treatment or prevention, as well as to a diagnostic method and a kit.
    Type: Application
    Filed: February 21, 2012
    Publication date: February 5, 2015
    Applicant: Plysackaridforskning i Uppsala AB
    Inventors: Ulf Lindahl, Jin-ping Li, Fredrik Noborn
  • Patent number: 8940888
    Abstract: Disclosed are chemically modified hyaluronic acid (HA) derivatives containing hydrazido groups directly linked to the glucuronic acid residues of HA. Said hydrazido groups are used to obtain crosslinked and labeled HA derivatives. The invention further relates to methods of preparation of said HA derivatives.
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: January 27, 2015
    Assignee: Prochon Biotech Ltd.
    Inventors: Boaz Amit, Avraham Wortzel, Avner Yayon
  • Patent number: 8937052
    Abstract: The present invention relates generally to the field of therapeutics and in particular, chemotherapy. Even more particularly, the present invention provides therapeutic strategies which reduce the toxicity or enhance the efficacy of chemotherapeutic agents. Compositions and methods of treatment and prophylaxis are also contemplated by the present invention.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: January 20, 2015
    Assignee: Alchemia Oncology Pty Limited
    Inventor: Tracey J. Brown
  • Publication number: 20150011505
    Abstract: The present invention relates to a chemically modified glycosaminoglycan with an antifactor II activity of less than 10 IU/mg, an antifactor Xa activity of less than 10 IU/mg and an average molecular weight (Mw, weight average) from about 4.6 to 6.9 kDa. Also disclosed is a method of preparing the modified glycosaminoglycan and its medical uses.
    Type: Application
    Filed: December 19, 2012
    Publication date: January 8, 2015
    Inventors: Hans-Peter Ekre, Ulf Lindahl, Erik Holmer, Per-Olov Eriksson
  • Publication number: 20140377330
    Abstract: The invention relates to a bioactive hydrogel as a hybrid material of heparin and star-branched polyethylene glycol with functionalized end groups, wherein the heparin is bound directly by reaction of the carboxyl groups activated with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimides/N-hydroxysulfosuccinimide (EDC/s-NHS) with the terminal amino groups of the polyethylene glycol covalently by amide bonds.
    Type: Application
    Filed: September 8, 2014
    Publication date: December 25, 2014
    Inventors: Carsten Werner, Uwe Freudenberg, Dorit Meinhold, Marie-Francoise Gouzy, Petra Welzel
  • Publication number: 20140377322
    Abstract: Disclosed is a multi-layered structure for drug reservoir, comprising a first micelle layer for crosslinking and adhesion, comprising a drug, a multi-arm polymer, a phenol derivative, and a dopa derivative and having a one or two-layered structure; a second micelle layer for crosslinking, being stacked on the first micelle layer, comprising a drug, a multi-arm polymer, and a phenol derivative, and having a one or two-layered structure; and a physiologically active material layer, being stacked on the second micelle layer, comprising a physiologically active material, a water-soluble polymer, and a phenol derivative, and having a one or two-layered structure.
    Type: Application
    Filed: June 20, 2014
    Publication date: December 25, 2014
    Inventors: Ki Dong PARK, Jong Hoon CHOI
  • Publication number: 20140377247
    Abstract: Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The compounds and compositions are useful in vitro or in vivo for preventing or treating coagulation disorders.
    Type: Application
    Filed: February 7, 2014
    Publication date: December 25, 2014
    Applicant: Millennium Pharmaceuticals, Inc.
    Inventors: Bing-Yan ZHU, Penglie ZHANG, Lingyan WANG, Wenrong HUANG, Erick A. GOLDMAN, Wenhao LI, Jingmei ZUCKETT, Yonghong SONG, Robert M. SCARBOROUGH
  • Publication number: 20140371171
    Abstract: The invention relates to an aqueous lock composition comprising a compound selected from the polysaccharide anti-coagulants and ethanol, and a method for locking an intravascular device implanted in a patient comprising the introduction of said composition into the device.
    Type: Application
    Filed: January 11, 2013
    Publication date: December 18, 2014
    Inventor: Bertrand Souweine
  • Patent number: 8912167
    Abstract: The invention provides the use in combination of a heparin containing composition that has anticoagulant activity when used alone, such as an unfractionated heparin or low molecular weight heparin, in combination with an inhibitor of the anticoagulation activity/effect or effect of heparin, for the inhibition of metastasis.
    Type: Grant
    Filed: May 21, 2012
    Date of Patent: December 16, 2014
    Inventor: Eugene J. Oliva